Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant  or a left ventricular assist device (LVAD).

One of the cardiology technologies in the list of top advances in 2019 is Medtronic’s Tyrx Absorbable Antibacterial Envelope using to enclose cardiac implantable electronic devices (CIEDs). It reduced the risk of major infection by 40 percent, and pocket infection by 61 percent, based on data presented at ACC 2019.

One of the cardiology technologies in the list of top advances in 2019 is Medtronic’s Tyrx Absorbable Antibacterial Envelope using to enclose cardiac implantable electronic devices (CIEDs). It reduced the risk of major infection by 40 percent, and pocket infection by 61 percent, based on data presented at ACC 2019.

News | November 06, 2019
November 6, 2019 — Cleveland Clinic announced the Top 10 Medical Innovations for 2020 at a multimedia presentation last...
Greater Left Ventricular Mass Increases Risk of Heart Failure
News | Magnetic Resonance Imaging (MRI) | October 21, 2019
October 21, 2019 — Elevated left ventricular mass, known as left-ventricular hypertrophy, is a stronger predictor of...
The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farxiga) to reduce the risk of hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Feature | Heart Failure | October 21, 2019 | Dave Fornell, Editor
October 21, 2019 – The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's...
Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
News | Heart Failure | October 16, 2019
October 16, 2019 — Researchers have shown for the first time in preclinical studies that the drug Aliskiren can delay...
The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019
October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve...
COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019
October 3, 2019 – The three-year results from the COAPT Trial demonstrated that reducing severe secondary mitral...
A MitraClip case underway at the University of Colorado Hospital hybrid cath lab. Left to right are doctors John Carroll, Edward Gill and Dominik Wiktor.

A MitraClip case underway at the University of Colorado Hospital hybrid cath lab. Left to right are doctors John Carroll, Edward Gill and Dominik Wiktor. (Photos by Dave Fornell)

Blog | University of Colorado Hospital | October 02, 2019
I recently had the opportunity to conduct an onsite visit to the University of Colorado Hospital Heart and Vascular...
Positive Safety, Efficacy Data Reported on AccuCinch Heart Failure Device
News | Heart Failure | September 27, 2019
September 27, 2019 — Ancora Heart Inc. announced results from an interim analysis of heart failure patients treated in...
Max and Debra Ernst Heart Center Opening at Beaumont Hospital, Royal Oak
News | Heart Failure | September 20, 2019
September 20, 2019 — The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept....
FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019
September 18, 2019 — AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.

News | Heart Failure | September 12, 2019
September 12, 2019 — Corvia Medical has sponsored and is actively enrolling patients in a heart failure (HF) device...
Reducing Secondary Mitral Regurgitation in Heart Failure Does Not Improve Two-year Outcomes
News | Heart Valve Technology | September 11, 2019
September 11, 2019 — Percutaneous reduction of secondary mitral regurgitation in patients with heart failure does not...
 Tiny Wearable Cameras May Improve Quality of Life in Heart Failure Patients

Image courtesy of Amazon.com

News | Heart Failure | September 11, 2019
September 11, 2019 — The ever-present devices that seem to track all our moves can be annoying, intrusive or worse, but...
PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019
September 11, 2019 — The angiotensin neprilysin inhibitor sacubitril/valsartan (Entresto) missed its primary endpoint...
Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure
News | Heart Failure | September 09, 2019
September 9, 2019 — AstraZeneca announced detailed results from the landmark Phase III DAPA-HF trial that showed...